Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in EGFR-mutant Lung Adenocarcinoma

Cancer Genomics - Proteomics

NAO HIROTA²  KYOHEI KABURAKI²  HAJIME OTSUKA¹  YUJIRO TAKAI²  AKIRA IYODA¹  SAKAE HOMMA²  TAKASHI MAKINO¹  FUMIAKI ISHIDA²  NAOBUMI TOCHIGI³  GO SANO²  KAZUTOSHI SHIBUYA³  SUSUMU SAKAMOTO²  KEISHI SUGINO²  KAZUTOSHI ISOBE²  HIROSHI KOBAYASHI²  YOSHINOBU HATA¹ 

[1] Division Chest Surgery, Toho University School of Medicine, Tokyo, JapaDivision Chest Surgery, Toho University School of Medicine, Tokyo, JapaDivision Chest Surgery, Toho University School of Medicine, Tokyo, Japa;Division of Respiratory Medicine, Toho University School of Medicine, Tokyo, JapaDivision of Respiratory Medicine, Toho University School of Medicine, Tokyo, JapaDivision of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japa;Department of Surgical Pathology, Toho University School of Medicine, Tokyo, JapaDepartment of Surgical Pathology, Toho University School of Medicine, Tokyo, JapaDepartment of Surgical Pathology, Toho University School of Medicine, Tokyo, Japa

关键词: Digital PCR;    non-small-cell lung cancer;    epidermal growth factor receptor tyrosine kinase inhibitor;    T790M;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Aim: The present pilot study assessed the usefulness of nanofluidic digital polymerase chain reaction (PCR) arrays in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma after tyrosine kinase inhibitor (TKI) resistance. Patients and Methods: We enrolled 12 patients with primary lung adenocarcinoma with sensitive EGFR mutation-confirmed T790M status by re-biopsy after TKI resistance. Nanofluidic digital PCR arrays were used to quantify T790M in genomic DNA from the pre-treatment primary site and in serum cell-free DNA (cfDNA). Results: On digital PCR, quantified T790M at the pre-treatment primary site was higher in re-biopsy-positive T790M patients (n=4) than in re-biopsy-negative patients (n=8) (0.78%±0.36% vs. 0.07%±0.09%, p<0.01). T790M at the pre-treatment primary site correlated with progression-free survival (PFS) after gefitinib therapy (r=0.67, p=0.016). Conclusion: Use of digital PCR to quantify T790M at the primary site of EGFR-mutant lung adenocarcinoma predicted T790M emergence in re-biopsies after TKI resistance and PFS after gefitinib therapy.

【 授权许可】

Unknown